Clinical trials
Lung Diseases, Interstitial trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
63 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 8 |
| 2023 | 6 |
| 2024 | 5 |
| 2025 | 4 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Recruiting | 13 |
| Unknown status | 8 |
| Active, not recruiting | 8 |
| Terminated | 6 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 11 |
| Schön Klinik Berchtesgadener Land | 5 |
| Bristol-Myers Squibb | 3 |
| Insmed Incorporated | 3 |
| United Therapeutics | 3 |
| Celgene | 2 |
| GlaxoSmithKline | 2 |
| Matthias Griese | 2 |
| University Hospital Tuebingen | 2 |
| Universitätsmedizin Mannheim | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Diseases, Interstitial | 63 |
| Idiopathic Pulmonary Fibrosis | 12 |
| Pulmonary Disease, Chronic Obstructive | 9 |
| Hypertension, Pulmonary | 7 |
| Pulmonary Fibrosis | 7 |
| Lung Diseases | 6 |
| Idiopathic Interstitial Pneumonias | 5 |
| Sarcoidosis | 5 |
| Scleroderma, Diffuse | 5 |
| Scleroderma, Systemic | 5 |
Trials
Showing 1 to 25 of 63. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.